Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 398

1.

Respiratory syncytial virus immune globulin: decisions and costs.

Barton LL, Grant KL, Lemen RJ.

Pediatr Pulmonol. 2001 Jul;32(1):20-8.

PMID:
11416872
2.

Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.

Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA.

Pediatrics. 1999 Sep;104(3 Pt 1):419-27.

PMID:
10469764
3.

Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis.

Lofland JH, O'Connor JP, Chatterton ML, Moxey ED, Paddock LE, Nash DB, Desai SA.

Clin Ther. 2000 Nov;22(11):1357-69.

PMID:
11117660
4.

Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group.

Rodriguez WJ, Gruber WC, Welliver RC, Groothuis JR, Simoes EA, Meissner HC, Hemming VG, Hall CB, Lepow ML, Rosas AJ, Robertsen C, Kramer AA.

Pediatrics. 1997 Mar;99(3):454-61.

PMID:
9041304
6.

Economic analysis of palivizumab in infants with congenital heart disease.

Yount LE, Mahle WT.

Pediatrics. 2004 Dec;114(6):1606-11.

PMID:
15574622
7.

Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.

Wegner S, Vann JJ, Liu G, Byrns P, Cypra C, Campbell W, Stiles A.

Pediatrics. 2004 Dec;114(6):1612-9.

PMID:
15574623
8.

Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.

Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM.

Arch Pediatr Adolesc Med. 2000 Jan;154(1):55-61.

PMID:
10632251
9.

Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children.

Rodriguez WJ, Gruber WC, Groothuis JR, Simoes EA, Rosas AJ, Lepow M, Kramer A, Hemming V.

Pediatrics. 1997 Dec;100(6):937-42.

PMID:
9374560
11.

Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.

American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn.

Pediatrics. 2003 Dec;112(6 Pt 1):1442-6.

PMID:
14654627
13.
15.

Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.

Meissner HC, Long SS; American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn.

Pediatrics. 2003 Dec;112(6 Pt 1):1447-52.

PMID:
14654628
16.

Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?

Hashmi NA, Cosgrove JF, MacMahon P.

Ir Med J. 2000 Dec;93(9):284.

PMID:
11209917
17.

Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.

Hampp C, Kauf TL, Saidi AS, Winterstein AG.

Arch Pediatr Adolesc Med. 2011 Jun;165(6):498-505. doi: 10.1001/archpediatrics.2010.298. Epub 2011 Feb 7.

PMID:
21300647
18.

Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.

Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J; IRIS Study Group.

Pediatr Infect Dis J. 2003 Sep;22(9):823-7.

PMID:
14506376
19.

Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review.

Kamal-Bahl S, Doshi J, Campbell J.

Arch Pediatr Adolesc Med. 2002 Oct;156(10):1034-41. Review.

PMID:
12361451

Supplemental Content

Support Center